Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOBEL: Nivolumab plus chemoradiotherapy for thoracic esophageal cancer
jRCT1091220408Completed
- Sponsor
- Manabu Muto
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in esophageal cancer, sponsored by Manabu Muto. Primary endpoint: Safety. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1091220408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220408.